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Background: Breast cancer is one of the most important neoplasia among women. To reduce its incidence and
mortality impact it would be desirable to early identify risk factors associated with its development. It was recently
suggested that biological agents could be the etiological cause, particularly Human Papilloma Virus (HPV). No
specific relationship with different breast cancer types has been demonstrated until now. In particular, the triple-negative
breast cancer (TNBC), characterized by a receptor negative pattern (ER/PgR/HER2–negative) and poor prognosis, can
represent one of the most relevant clinical and public health priority in terms of observational research.
Findings: Aim of the study was to evaluate the HPV-positivity prevalence in two breast cancer series (TNBC
vs. non-TNBC) in Northern Sardinia, Italy. The sample size of each group was represented by 40 formalin-fixed
and paraffin-embedded specimens. The mean age was 60.3 years. The majority of the cancers were ductal
(84%). The grading distribution was different: G2 was the most prevalent grade in the non-TNBC series, whereas
G3 was the most frequent in the TNBC series (70% and 72%, respectively). Six biological samples were HPV-positive
(7.5%): the positivity was assessed only in the TNBC group (15%; p-value: 0.026). The isolated genotypes were: 16, 31,
45, 52, 6, and 66. Only one co-infection was found (i.e., HPV-6 and -66).
Conclusions: The prevalence of HPV-positivity in TNBC specimens was 15%. On the basis of its carcinogenetic ability,
an etiological role in the pathogenesis of the cancer could be supposed. This association should be confirmed with
longitudinal studies to better assess the role of the HPV infection in TNBC and non-TNBC tumors.Findings
Breast cancer is the most common cancer and the principle
cause of death from cancer in women worldwide [1].
Although reduction of global mortality might be achieved
with early diagnosis selecting individuals on the basis of
well-known risk factors (i.e., age, familial history, and a pre-
vious history of breast cancer), the majority of the cases in
low- and middle-income countries cannot be diagnosed
with a secondary prevention strategy. Moreover, risk factors
may be not recognized in a large proportion of patients [2].
Therefore, it is crucial to confirm the role of other
suspected risk factors, such as viral infections due to* Correspondence: gsotgiu@uniss.it
†Equal contributors
1Hygiene and Preventive Medicine, Department of Biomedical Sciences,
University of Sassari, Sassari, Italy
3Epidemiology and Medical Statistics Unit, Department of Biomedical
Sciences, University of Sassari - Research, Medical Education and Professional
Development Unit, AOU Sassari, Sassari, Italy
Full list of author information is available at the end of the article
© 2014 Piana et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Epstein-Barr virus, mouse mammary tumor virus, and
human papilloma virus (HPV). To date, the relationship be-
tween HPV and breast cancer has not been fully elucidated:
sexual transmission, by direct contact with genital region,
and/or hematological spread [3] from genital lesions should
be considered. The potential causal association between
HPV infection and breast cancer was firstly described in
1992 [4]; however, some Authors confirmed the relation-
ship in association with different HPV prevalence estimates
[5-10] but others did not [11-13]. Incongruous findings
may depend on the assay methods, HPV prevalence,
and geographic differences [14-16]; besides, very few
studies evaluated the association between HPV infec-
tion and breast cancer clinical-pathologic features, such
as histologic subtypes, tumor grade, hormone receptors
expression and Human Epidermal Growth Factor Receptor
2 (HER2) status [17-19].
In clinical practice, according to a recent molecular clas-
sification, immunohistochemical expression of Estrogentd. This is an Open Access article distributed under the terms of the Creative
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to categorize breast cancers in different prognostic sub-
groups (luminal A, luminal B, HER2 overexpressing, and
triple negative breast cancers [TNBC]), with distinct
therapeutic approaches [20]. In particular, the TNBC
phenotype (ER/PgR/HER2–negative), which accounts for
10-24% of invasive breast cancers, is characterized by earlier
onset, poor prognosis, and limited therapeutic options [3],
therefore, it may represent a priority epidemiological
research target [21].
Recently, our group performed a case–control investiga-
tion, which described a high overall prevalence of HPV
cervical infection in women living in Northern Sardinia,
Italy. In particular, HPV types −16 and −51 DNA were
detected in 12.5 and 6.3% of atypical squamous cells of
undetermined significance; 24.0% and 16.0% of low-grade
squamous intraepithelial lesions; 50.0% and 50.0% of high-
grade squamous intraepithelial lesions, respectively [22].
Moreover, these figures were confirmed by a further retro-
spective study in embedded invasive cervical cancers,
which highlighted the primary role of HPV-16 in the
pathogenesis of cervical carcinoma followed by an un-
usual high prevalence of HPV-51 infection (36.2%)
[23]. The recent availability of two HPV vaccines, rec-
ommended for the primary cervical cancer prevention,
could imply the potential advantage of immunization
practices in preventing other HPV-related cancers.
On this basis, we carried out a case–control study
aimed at identifying the presence of HPV-DNA in em-
bedded tissues series of TNBC diagnosed in women
from Northern Sardinia.
Ethical approval and informed consent for this study
was unnecessary, according to the Italian legislation con-
cerning the guidelines for the performance of observa-
tional studies (G.U. n. 76. 31-3-2008). However, a formal
approval of the study protocol was requested in 2013 to
the Ethical Committee of the Azienda Sanitaria Locale
n°1 of Sassari, Italy (PN-1137/L 2013).
A case–control study, based on a case–control design,
was performed to evaluate the prevalence of HPV infec-
tion in a subset of 40 embedded TNBC and 40 embedded
non-TNBC, as controls; both groups of breast cancer
series belonged to women admitted to a tertiary University
Hospital located in Sassari, Italy.
An ad-hoc case report form was created to record
demographic, histopathological and virological informa-
tion. Data were anonymized in compliance with the Law
Decree No. 196/2003, article 24 (Code for the protection
of personal data).
Based on a sample size calculation, 40 formalin-fixed
and paraffin-embedded (FFPE) tissues from TNBC spec-
imens were consecutively and retrospectively selected
from the pool of those collected in the Pathology Unit,
Department of Clinical and Experimental Medicine,University of Sassari. The selection of every TNBC spe-
cimen was associated with a FFPE non-TNBC specimen,
as control, paired by age (±5 years). The enrolled series
was diagnosed by a pathologist who was blinded to the
final diagnosis. The same methodological blinding pro-
cedure was followed for the virological analysis, carried
out in triplicate at the WHO quality-assured laboratory of
the Hygiene and Preventive Medicine Unit, Department
of Biomedical Sciences, University of Sassari (http://www.
who.int/biologicals/areas/vaccines/hpv_labnet/en/).
Ten consecutive sections, 10 micron in thickness, were
cut under sterile conditions from representative neoplastic
tissue blocks of 80 breast cancers, in order to obtain gen-
omic DNA. Nucleic acids were extracted with a commer-
cially available extraction kit (QIAamp DNA FFPE Tissue
Kit, Qiagen, Hilden, Germany) in accordance with the
manufacturer’s instructions. To obtain genomic DNA
10ul of RNase A (20 mg/ml, Rnase PureLink, Life Tech-
nologies) were applied directly to the silica membrane to
digest contaminating RNA. The quantity and the quality
of nucleic acids were assessed spectrophotometrically (260
nm, 260/280 and 260/230 ratios, spectrum 220–320 nm)
using Nanodrop ND1000 (EuroClone, Milan, Italy).
Positive and negative controls were represented by
HPV-positive samples and water blanks, respectively
HPV DNA sequences were detected with the INNO-
LiPA HPV Genotyping Extra kit (Innogenetics, Gent,
Belgium), based on the reverse hybridization principle,
according to manufacturer’s instructions. The INNO-LiPA
assay covers all currently known high-risk HPV genotypes,
such as high-risk (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73, 82), low-risk HPV genotypes
(HPV 6, 11, 40, 43, 44, 54, 70), and some additional types
(HPV 69, 71, 74), while HPV 13, 34 and 67 genotypes are
interpreted as HPV X. The INNO-LiPA assay utilizes a
cocktail of biotinylated consensus primers (SPF10) to
amplify a 65-bp region within the L1 Open Reading
Frame of multiple HPV types. The biotinylated PCR prod-
ucts are then genotyped by hybridization to HPV type-
specific oligonucleotide probes bound to nitrocellulose
membranes and detected by an alkaline phosphatase-
streptavidin conjugate and colorimetric detection. Post-
PCR hybridization and colorimetric detection were per-
formed using the Auto-LiPA 48 instrument in accordance
with the manufacturer’s recommendations. At the end of
color development, the strips were scanned and evaluated
by the Line Reader and Analysis software (LiRAS) to de-
termine if defined bands for a particular genotype probe
were visible. A biological sample is considered HPV posi-
tive if at least one of the type-specific lines or one of the
HPV control lines is positive. An additional primer pair for
the amplification of the human HLA-DPB1 gene is added
to monitor sample quality and extraction. When positivity
for HR genotypes −16, −18, −31, −45, −51, and −52 was
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ples with an “in-house” Real-Time quantitative TaqMan
PCR assay [11,22].
The sample size, calculated considering a first type
error of 0.05, based on a case control ratio of 1:1, and an
estimated exposure prevalence of 0.134, computed pooling
proportions of 7 studies conducted in Europe [12], with a
statistical power of 0.8 for an OR≥4, required 40 cases.
Qualitative variables were summarized with percentages
and were statistically compared using the z-proportion
hypothesis test. Chi-square or Fisher exact test was used
when appropriate. A p-value <0.05 was considered statis-
tically significant. Statistical analysis was carried out
using the statistical software Stata 11.0 (StataCorp LP,
College Station, Texas).
A total of 80 embedded breast cancer specimens were
analyzed: 40 were TNBC and 40 were embedded non-
TNBC, namely 38 “luminal A” and 2 “HER2 overexpress-
ing” variants. The mean (standard deviation) age of the
patients was 60.3 (14.2) years; in particular, it was 60.3
(15.8) and 60.3 (12.6) for TNBC cases and controls,
respectively (p-value: 0.99). Patients’ characteristics and
pathology features are described in Table 1.
According to histopathological classification, the majority
of the cancers were ductal (67, 83.8%), followed by lobular
(5, 6.3%), and others (8, 10%). The proportional grading
distribution in the entire series was the following: G1 7.6%
(n = 6), G2 49.4% (n = 39), and G3 43.0% (n = 34); in
particular, G1 0.0% (n = 0), G2 28.2% (n = 11), and G3
71.8% (n = 28) for the TNBC cases; conversely, the propor-
tion for the non-TNBC controls was G1 15.0% (n = 6), G2
70.0% (n = 28), and G3 15.0% (n = 6) (p-value <0.0001).
Out of 80 patients six (7.5%, 95% confidence intervals:
1.7-13.0) were positive for at least one HPV genotype. In
particular, HPV positivity was detected only among the 40
TNBC (15.0%; p-value = 0.026). The most frequent geno-
types were HPV-16 (28.6%), −31 (14.3%), −45 (14.3%), −52
(14.3%), −6 (14.3%), −66 (14.3%); the only co-infection de-
tected was HPV-6 and HPV-66.Table 1 Demographic, pathological, and virological character
Variables n = 80
Mean age (SD), years 60.3 (14.2)
Histotype, n (%) Invasive ductal 67 (83.8)
Invasive lobular 5 (6.3)
Others 8 (10.0)
Grading, n (%) 1 6 (7.6)
2 39 (49.4)
3 34 (43.0)
HPV+, n (%) [CI 95%] 6 (7.5) [1.7-13.3]
SD: Standard Deviation.
CI: Confidence Interval.Logistic regression analysis did not identify covariates
associated with HPV-positivity (results not showed).
HPV genome was detected in approximately 8% of the
cases suggesting a viral pathogenesis of the cancer on
the basis of its well known role in the carcinogenesis of
the epithelial cells [14], even if the proportion found was
below the average value assessed by other Authors [16,19].
However, the study we performed was not designed to
evaluate the prevalence, being a case–control study, but to
focus on the relationship between HPV infection and
TNBC and to demonstrate its potential etiopathogenetic
role in this kind of tumors.
The difference in terms of cellular differentiation was
striking: the proportion of G3 was significantly higher in
the TNBC group than in the non-TNBC category. How-
ever, no differences for the histological type were found,
since the majority of the carcinomas showed ductal
differentiation.
TNBC were the most undifferentiated carcinomas:
they were the only neoplastic type found positive to the
molecular analysis aimed at diagnosing HPV DNA. The
non-TNBC series were HPV negative, and the difference
in terms of positivity was statistically significant.
A more prevalent genotype was not identified: those
detected were genotypes usually identified in the geo-
graphical context where this epidemiological study was
carried out [22,23].
Even if the study carried out in our center detected only
HPV-positivity in the TNBC, the probability of virological
positive results in other cancers showing different receptor
patterns could be hypothesized (e.g., [10]). Nevertheless,
other studies confirmed that HPV-positivity can be fre-
quently found in estrogen-receptor negative tumors or in
those characterized by a high proliferation rate [9].
At our best knowledge, our research is one of the first
observational studies proving an association between
TNBC phenotype and HPV-positivity. Moreover, our
findings strengthen the hypothesis of an association
between HPV-positivity and poorly differentiated variants.istics of the selected cohort
Triple-negative Other receptor pattern p-value
(n = 40) (n = 40)
60.3 (15.8) 60.3 (12.6) 0.99
31 (77.5) 36 (90.0) 0.11
2 (5.0) 3 (7.5)
7 (17.5) 1 (2.5)
0 (0.0) 6 (15.0) <0.0001
11 (28.2) 28 (70.0)
28 (71.8) 6 (15.0)
6 (7.5) [1.7-13.0] 0 (0.0) [0.0-0.0] 0.026
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future studies, should be carefully evaluated because only
a few HPV positive cases were identified and other studies
found HPV in breast tissues with estrogen-receptor
expression [24]. Moreover, the low viral load, detected in
several studies [25,26], can explain the low frequency of
HPV-positive series.
Furthermore, the explanation of the role played by the
host susceptibility will be necessary, proving if the genetic
background can predispose to an imbalance of the native
and/or adaptive immunity favoring the infection in that
specific anatomical area, as well as the activation of an
uncontrolled proliferation cycle.
The demonstration of the etiologic role of the HPV
infection could be relevant, particularly because of the
availability of highly efficacious preventive vaccines; in
case of a research concordance on the role of HPV, this
primary prevention strategy could increase the arma-
mentarium of the current tools implemented in the
breast cancer prevention.
This study shows some limitations. Its retrospective
nature cannot assess if HPV infection precedes the can-
cer development. However, the epidemiological nature
of the study, i.e. the case/control design, is the one sug-
gested in case of rare events. The sample size is smaller
than the statistical population size but, in order to avoid
unreliable results related to unpowered studies, we com-
puted the hypothesized sample size representative of the
current population on the basis of several epidemiology-
based assumptions. Furthermore, we could not assess the
pathogenetic role of the HPV genotypes: new molecular
hybridization in situ studies are needed to evaluate the
cellular location and the pattern of hybridization of the
HPV genome, that is to evaluate if the HPV-DNA is inte-
grated in the human DNA or shows episomal replication
in the neoplastic nuclei. It is straightforward that the inte-
gration in the human genome can alter the control of the
cellular duplication cycle. Another study we are perform-
ing will try to answer to that relevant pathogenetic issue.
The risk of a cross-contamination was avoided adopting
sterile procedures during the preparation of the biological
samples; the methodological efficacy of the molecular proce-
dures was indirectly demonstrated by the detection of six
different genotypes out of six positive TNBC samples.
Another unsolved problem is the origin of the HPV: to
understand the original site of infection is important for
the identification of preventive measures. On this basis,
a concomitant virological study on cervical and/or oral-
laryngeal samples could have allowed to appreciate if the
sexual transmission has a role in the human spread of
HPV types [14]. Unfortunately, the missing systematic
cervical cancer screening of the patients in Sardinia did
not allow the detection of HPV infection in other ana-
tomical sites for the individuals enrolled in our study.It is clear that the immunization programs, carried out
in young adults, could play a role in the near future in
the protection against those genotypes involved in the
cancer pathogenesis and included in the currently available
vaccines. However, the low prevalence of HPV suggests
that other epidemiological, demographic (e.g., genetic
background), clinical, virological risk factors should be
assessed to better understand the potential synergistic or
additive pathogenetic role of HPV genotypes.
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